Botanix Pharmaceuticals Limited
BXPHF
$0.25
$0.000.00%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.36M | 1.36M | 1.36M | 822.90K | 287.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.36M | 1.36M | 1.36M | 822.90K | 287.00K |
| Cost of Revenue | 2.56M | 2.48M | 2.40M | 1.73M | 1.07M |
| Gross Profit | -1.20M | -1.12M | -1.04M | -907.90K | -782.20K |
| SG&A Expenses | 24.46M | 16.28M | 7.83M | 6.54M | 5.28M |
| Depreciation & Amortization | 781.10K | 419.50K | 47.70K | 57.90K | 68.80K |
| Other Operating Expenses | 266.70K | 266.70K | 266.70K | 395.10K | 529.80K |
| Total Operating Expenses | 28.06M | 19.45M | 10.54M | 8.72M | 6.95M |
| Operating Income | -26.70M | -18.08M | -9.18M | -7.90M | -6.66M |
| Income Before Tax | -25.94M | -17.66M | -9.10M | -7.86M | -6.65M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.94 | -17.66 | -9.10 | -7.86 | -6.65 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.94M | -17.66M | -9.10M | -7.86M | -6.65M |
| EBIT | -26.70M | -18.08M | -9.18M | -7.90M | -6.66M |
| EBITDA | -25.92M | -17.67M | -9.14M | -7.87M | -6.65M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Diluted EPS | -0.01 | -0.01 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 6.76B | 6.38B | 6.01B | 5.73B | 5.45B |
| Average Diluted Shares Outstanding | 6.76B | 6.38B | 6.01B | 5.73B | 5.45B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
